The U.S. Food and Drug Administration has once again refused to approve a liver cancer treatment developed by China's Jiangsu Hengrui Pharmaceuticals and its U.S. partner Elevar Therapeutics.
According to Endpoints News, this marks the third rejection in about two years for the drug combination, which is intended to treat the most common form of liver cancer. In each case, the FDA has pointed to the same underlying issue: manufacturing deficiencies.
That distinction matters. The agency's concerns, as reported by Endpoints News, center on how the treatment is made rather than on whether it works in patients. Manufacturing problems — often tied to how a factory documents, controls, or maintains the quality of a drug's production — can stall an otherwise promising therapy for years until a company brings its facilities and processes up to the FDA's standards.
For Hengrui, one of China's largest drugmakers, and for Elevar, the repeated setbacks delay a potential entry into the competitive market for liver cancer therapies and push back any revenue the combination might generate. Endpoints News did not report a new timeline for when the companies might address the deficiencies and try again.
Why it matters: A drug that keeps failing on manufacturing grounds rather than on medical results shows how far a treatment can advance scientifically yet still be kept from patients by problems on the factory floor.